Aemetis Q2 EPS Decreased by Ascendiant Capital Markets

Key Points

• Ascendiant Capital Markets cut its Q2 2026 EPS estimate for Aemetis to ($0.21) from ($0.20) but kept a Buy rating and a $21 price target.
• Aemetis reported Q1 EPS of ($0.24), beating the consensus by $0.04, while revenue of $43.3M significantly missed the $72.1M estimate.
• The stock trades around $2.28 with a market cap of $155M, a consensus analyst rating of Hold and a consensus target price of $8.58, and roughly 27% institutional ownership.

Aemetis, Inc (NASDAQ:AMTX - Free Report) - Equities researchers at Ascendiant Capital Markets reduced their Q2 2026 earnings per share estimates for shares of Aemetis in a note issued to investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo now expects that the specialty chemicals company will post earnings per share of ($0.21) for the quarter, down from their previous forecast of ($0.20). Ascendiant Capital Markets has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Aemetis' current full-year earnings is ($2.07) per share. Ascendiant Capital Markets also issued estimates for Aemetis' Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.86) EPS.

Aemetis (NASDAQ:AMTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The specialty chemicals company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $43.31 million for the quarter, compared to the consensus estimate of $72.07 million.

Several other research firms have also issued reports on AMTX. Wall Street Zen upgraded Aemetis from a "sell" rating to a "hold" rating in a research report on Sunday, March 22nd. Loop Capital set a $1.75 price target on Aemetis in a research report on Thursday, March 12th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Aemetis currently has a consensus rating of "Hold" and a consensus target price of $8.58.

Aemetis Price Performance

AMTX opened at $2.28 on Wednesday. The stock's 50 day simple moving average is $2.11 and its 200 day simple moving average is $1.97. Aemetis has a 1 year low of $1.22 and a 1 year high of $3.66. The firm has a market cap of $155.38 million, a price-to-earnings ratio of -1.71 and a beta of 1.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new position in shares of Aemetis in the 2nd quarter valued at approximately $30,000. Virtu Financial LLC purchased a new position in shares of Aemetis in the 4th quarter valued at approximately $31,000. HRT Financial LP purchased a new position in shares of Aemetis in the 4th quarter valued at approximately $36,000. Centiva Capital LP purchased a new position in shares of Aemetis in the 3rd quarter valued at approximately $39,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Aemetis in the 2nd quarter valued at approximately $42,000. Hedge funds and other institutional investors own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.